PL3076967T3 - Metody leczenia objawów rezydualnych schizofrenii - Google Patents

Metody leczenia objawów rezydualnych schizofrenii

Info

Publication number
PL3076967T3
PL3076967T3 PL14867061T PL14867061T PL3076967T3 PL 3076967 T3 PL3076967 T3 PL 3076967T3 PL 14867061 T PL14867061 T PL 14867061T PL 14867061 T PL14867061 T PL 14867061T PL 3076967 T3 PL3076967 T3 PL 3076967T3
Authority
PL
Poland
Prior art keywords
schizophrenia
treatment
methods
residual symptoms
symptoms
Prior art date
Application number
PL14867061T
Other languages
English (en)
Inventor
Kimberly Vanover
Peng Li
Sharon Mates
Robert Davis
Lawrence P. Wennogle
Original Assignee
Intra-Cellular Therapies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53274093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3076967(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intra-Cellular Therapies, Inc. filed Critical Intra-Cellular Therapies, Inc.
Publication of PL3076967T3 publication Critical patent/PL3076967T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL14867061T 2013-12-03 2014-12-03 Metody leczenia objawów rezydualnych schizofrenii PL3076967T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361911416P 2013-12-03 2013-12-03
US201461925607P 2014-01-09 2014-01-09
US201461975702P 2014-04-04 2014-04-04
US201462032326P 2014-08-01 2014-08-01
EP14867061.5A EP3076967B1 (en) 2013-12-03 2014-12-03 Methods for treating residual symptoms of schizophrenia
PCT/US2014/068443 WO2015085004A1 (en) 2013-12-03 2014-12-03 Novel methods

Publications (1)

Publication Number Publication Date
PL3076967T3 true PL3076967T3 (pl) 2021-12-20

Family

ID=53274093

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14867061T PL3076967T3 (pl) 2013-12-03 2014-12-03 Metody leczenia objawów rezydualnych schizofrenii

Country Status (17)

Country Link
US (8) US9956227B2 (pl)
EP (2) EP3666271A1 (pl)
JP (5) JP6475727B2 (pl)
KR (8) KR20230058736A (pl)
CN (2) CN114366741A (pl)
AU (4) AU2014360452C1 (pl)
BR (1) BR112016012781A2 (pl)
CA (4) CA2932610C (pl)
DK (1) DK3076967T3 (pl)
ES (1) ES2893621T3 (pl)
HU (1) HUE056496T2 (pl)
IL (4) IL321987A (pl)
MX (3) MX383855B (pl)
PL (1) PL3076967T3 (pl)
PT (1) PT3076967T (pl)
RU (1) RU2682658C1 (pl)
WO (1) WO2015085004A1 (pl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101805914B1 (ko) 2007-03-12 2017-12-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
AU2009251816B2 (en) * 2008-05-27 2015-12-10 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
CA2741731A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
HUE043962T2 (hu) 2009-10-23 2019-09-30 Janssen Pharmaceutica Nv Diszubsztituált oktahidro-pirrolo[3,4-C]pirrolok mint orexin receptor modulátorok
CN103209704B (zh) 2010-04-22 2017-10-27 细胞内治疗公司 有机化合物
AU2013245702A1 (en) 2012-04-14 2014-11-13 Intra-Cellular Therapies, Inc. Organic compounds
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2015085004A1 (en) 2013-12-03 2015-06-11 Intra-Cellular Therapies, Inc. Novel methods
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
KR20170012210A (ko) 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US10603272B2 (en) 2015-02-27 2020-03-31 Kindred Biosciences, Inc. Stimulation of appetite and treatment of anorexia in dogs and cats
EP3322415A4 (en) * 2015-07-15 2019-03-13 Axovant Sciences GmbH DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE
WO2017117514A1 (en) * 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
CN105560192A (zh) * 2016-01-07 2016-05-11 万全万特制药江苏有限公司 一种棕榈酸帕利哌酮长效微球注射液的制备方法
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
CN108883110B (zh) 2016-03-10 2022-05-27 詹森药业有限公司 使用食欲素-2受体拮抗剂治疗抑郁症的方法
DK3407889T3 (da) 2016-03-25 2021-08-09 Intra Cellular Therapies Inc Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規塩類および結晶
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
TW202515564A (zh) * 2016-12-02 2025-04-16 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
CN110087640A (zh) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018175969A1 (en) * 2017-03-24 2018-09-27 Intra-Cellular Therapies, Inc. Novel compositions and methods
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
CA3071137A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Prodrugs of substituted heterocycle fused gamma-carbolines
CN111093665A (zh) 2017-07-26 2020-05-01 细胞内治疗公司 有机化合物
JP2020535231A (ja) 2017-09-26 2020-12-03 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規な塩および結晶
SG11202003194YA (en) 2017-10-10 2020-05-28 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
KR102089737B1 (ko) 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
CN118593482A (zh) 2017-12-05 2024-09-06 赛诺维信制药公司 非外消旋混合物及其用途
US10377708B2 (en) 2017-12-05 2019-08-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US11980617B2 (en) 2018-03-16 2024-05-14 Intra-Cellular Therapies, Inc. Methods of treating acute depression and/or acute anxiety
WO2019183341A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
MX2020013116A (es) 2018-06-06 2021-05-12 Intra Cellular Therapies Inc Sales y cristales novedosos.
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
JP7483671B2 (ja) 2018-06-11 2024-05-15 イントラ－セルラー・セラピーズ・インコーポレイテッド 置換ヘテロ環縮合ガンマ－カルボリン類合成
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
BR112021001738A2 (pt) 2018-06-21 2021-06-29 Aquestive Therapeutics, Inc. sistema e método para fabricação de doses unitárias individuais personalizadas contendo ativos farmacêuticos
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019331490B2 (en) * 2018-08-31 2025-04-24 Intra-Cellular Therapies, Inc. Novel methods
JP7546546B2 (ja) * 2018-08-31 2024-09-06 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
CN112955124A (zh) 2018-09-07 2021-06-11 阿奎蒂夫疗法公司 具有精确的活性物溶出谱的口腔膜组合物和剂型
JP7487204B2 (ja) 2018-12-17 2024-05-20 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2020131911A1 (en) 2018-12-17 2020-06-25 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
WO2020132474A1 (en) 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compound
JP7649743B2 (ja) 2018-12-21 2025-03-21 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
KR20200087594A (ko) 2019-01-11 2020-07-21 한국화학연구원 레티노익산을 포함하는 미립구형 서방출 제제 및 그의 제조방법
JP2022535893A (ja) 2019-06-04 2022-08-10 サノビオン ファーマシューティカルズ インク 放出調節製剤およびその使用
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
US12478623B2 (en) * 2019-09-25 2025-11-25 Intra-Cellular Therapies, Inc. Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor
MX2022004983A (es) 2019-11-01 2022-09-23 Aquestive Therapeutics Inc Composiciones de profarmaco y metodos de tratamiento.
CN115038451A (zh) 2019-11-14 2022-09-09 阿奎斯蒂弗医疗股份有限公司 多模式组合物和治疗方法
JP7261942B2 (ja) 2019-12-11 2023-04-20 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
US11344503B2 (en) * 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations
EP4076461A4 (en) * 2019-12-19 2024-01-03 Intra-Cellular Therapies, Inc. Methods of schizophrenia treatment
KR102383448B1 (ko) 2020-04-20 2022-04-06 한국화학연구원 락트산 또는 글리콜산을 포함하는 미립구형 서방출 제제 및 그의 제조방법
US20220233471A1 (en) 2021-01-15 2022-07-28 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
US11992559B2 (en) 2021-02-24 2024-05-28 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
EP4304554A1 (en) 2021-03-09 2024-01-17 Aquestive Therapeutics, Inc. Dosage forms having equivalent biocomparable profiles
AU2023204432A1 (en) * 2022-01-03 2024-07-18 Engrail Therapeutics, Inc. Deuterated organic compounds and uses thereof
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
AU2023272111A1 (en) 2022-05-18 2024-11-28 Intra-Cellular Therapies, Inc. Novel methods
JP2024171855A (ja) 2023-05-30 2024-12-12 株式会社ダイセル 樹脂組成物
WO2025010266A1 (en) 2023-07-02 2025-01-09 Engrail Therapeutics, Inc. Deuterated organic compounds and uses thereof
WO2025111568A1 (en) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
WO2025240804A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices and methods

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490813A (en) 1944-11-29 1949-12-13 Standard Oil Co Continuous process for making aryl amines
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US3914421A (en) * 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
IE41352B1 (en) 1974-04-01 1979-12-19 Pfizer 5-aryl-1,2,3,4-tetrahydro- -carbolines
US4001263A (en) 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4522944A (en) 1982-12-23 1985-06-11 Erba Farmitalia Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
ZA871987B (en) 1986-03-19 1988-05-25 Kumiai Chemical Industry Co 5h-1,3,4-thiadiazole(3,2-a)pyrimidin-5-one derivatives and fungicidal compositions containing the same
ES2058069T3 (es) 1986-04-07 1994-11-01 Kumiai Chemical Industry Co Derivados de 5h-1,3,4-tiadiazolo-(3,2-a)-pirimidin-5-ona y nuevo compuesto fungicida agricola-horticola que contiene dicho derivado.
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
IT1271352B (it) 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
HU219487B (hu) * 1993-11-19 2001-04-28 Janssen Pharmaceutica Nv. Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk
CA2186371A1 (en) 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
US5654482A (en) 1996-02-29 1997-08-05 Xerox Corporation Triarylamine processes
US5648539A (en) 1996-02-29 1997-07-15 Xerox Corporation Low temperature arylamine processes
US5648542A (en) 1996-02-29 1997-07-15 Xerox Corporation Arylamine processes
US5847166A (en) 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
US5723669A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5723671A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
GB2328686B (en) 1997-08-25 2001-09-26 Sankio Chemical Co Ltd Method for producing arylamine
US6884429B2 (en) 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US6395939B1 (en) 1997-10-06 2002-05-28 Massachusetts Institute Of Technology Diaryl ether condensation reactions
US6235936B1 (en) 1998-02-26 2001-05-22 Massachusetts Institute Of Technology Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates
JP4647780B2 (ja) 1998-02-26 2011-03-09 マサチューセッツ インスティテュート オブ テクノロジー ヒドラジン、ヒドラゾン、ヒドロキシルアミンおよびオキシムの金属−触媒アリール化およびビニル化
US5902901A (en) 1998-05-07 1999-05-11 Xerox Corporation Arylamine processes
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
DE69935933T2 (de) 1998-07-10 2008-01-10 Massachusetts Institute Of Technology, Cambridge Liganden für Metalle und verbesserte Metall-katalysierte Verfahren, die darauf basieren
US20010008942A1 (en) 1998-12-08 2001-07-19 Buchwald Stephen L. Synthesis of aryl ethers
CN1161101C (zh) 1998-12-17 2004-08-11 阿尔扎有限公司 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统
NO309305B1 (no) 1999-02-19 2001-01-15 Norsk Hydro As Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
HK1043112A1 (zh) 1999-06-15 2002-09-06 Bristol-Myers Squibb Pharma Company 取代的稠杂环γ-咔啉
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US6541639B2 (en) 2000-07-26 2003-04-01 Bristol-Myers Squibb Pharma Company Efficient ligand-mediated Ullmann coupling of anilines and azoles
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
HUP0303432A3 (en) 2000-12-20 2012-09-28 Bristol Myers Squibb Co Substituted pyridoindoles as serotonin agonists and antagonists and pharmaceutical compositions containing the compounds and their use
EP1390340B1 (en) 2001-04-24 2017-03-01 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
DE10123129A1 (de) 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
WO2003014118A1 (en) 2001-08-08 2003-02-20 Pharmacia & Upjohn Company THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES
EP1314554A1 (fr) 2001-11-23 2003-05-28 Kba-Giori S.A. Dispositif de décollage d'éléments de sécurité
DE10162121A1 (de) 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
JP4500679B2 (ja) 2002-07-29 2010-07-14 アルザ・コーポレーシヨン パリペリドンを制御送達する方法および投薬形態物
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US6888032B2 (en) 2002-08-02 2005-05-03 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
US20040142970A1 (en) 2002-11-01 2004-07-22 Kathryn Chung Treatment of hyperkinetic movement disorder with donepezil
ES2364046T3 (es) 2002-12-19 2011-08-23 Bristol-Myers Squibb Company Gamma-carbolinas tricíclicas sustituidas utilizadas como agonistas y antagonistas de los receptores de la serotonina.
ATE407117T1 (de) * 2003-01-16 2008-09-15 Acadia Pharm Inc Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
CN1852893A (zh) 2003-07-21 2006-10-25 史密丝克莱恩比彻姆公司 (2S,4S)－4－氟－1－[4－氟－β－(4－氟苯基)－L－苯基丙氨酰基]－2－吡咯烷甲腈对甲苯磺酸盐及其无水晶体形式
TW200514785A (en) 2003-09-26 2005-05-01 Solvay Pharm Bv Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity
JP2005259113A (ja) 2004-02-12 2005-09-22 Ricoh Co Ltd プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法
EP1756102A1 (en) 2004-03-05 2007-02-28 Pharma C S.A. 8-PHENOXY-GammaCARBOLINE DERIVATIVES
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
WO2006034187A2 (en) 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
WO2006032999A1 (en) 2004-09-21 2006-03-30 Pfizer Products Inc. N-methyl hydroxyethylamine useful in treating cns conditions
US7614727B2 (en) 2004-09-30 2009-11-10 Fujifilm Corporation Liquid ejection head, manufacturing method thereof, and image forming apparatus
MX2007006896A (es) 2004-12-15 2007-06-26 Hoffmann La Roche Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer.
KR20070099031A (ko) 2005-01-25 2007-10-08 셀진 코포레이션 4-아미노-2-(3-메틸-2,6-디옥소피페리딘-3-일)-이소인돌-1,3-디온을 사용한 방법 및 조성물
CA2595607C (en) 2005-01-25 2014-07-15 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
US20090104274A1 (en) * 2005-03-01 2009-04-23 Ajay Khopade Process of making microspheres
US20080194592A1 (en) 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
JP2009523734A (ja) 2006-01-13 2009-06-25 ワイス ５−ヒドロキシトリプタミン受容体のためのリガンドとしてのスルホニル置換された１ｈ−インドール
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
KR101805914B1 (ko) * 2007-03-12 2017-12-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
WO2009017836A1 (en) 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
EP2190844B3 (en) 2007-08-15 2013-07-17 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US20090209608A1 (en) 2007-08-29 2009-08-20 Protia, Llc Deuterium-enriched asenapine
US20090076159A1 (en) 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched eplivanserin
EP2262502A4 (en) 2008-02-05 2011-12-28 Clera Inc Compositions and methods for alleviating depression or improving cognition
EP2250199B1 (en) 2008-02-07 2015-09-02 Merck Sharp & Dohme Corp. Engineered anti-tslpr antibodies
MX2010010024A (es) * 2008-03-12 2010-11-09 Intra Cellular Therapies Inc Solido de gamma-carbolinas fusionadas con heterociclos substituidos.
AU2009251816B2 (en) * 2008-05-27 2015-12-10 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
US8309772B2 (en) 2008-07-31 2012-11-13 Celanese International Corporation Tunable catalyst gas phase hydrogenation of carboxylic acids
WO2010037142A1 (en) * 2008-09-29 2010-04-01 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US20100159033A1 (en) 2008-09-29 2010-06-24 Auspex Pharmaceuticals, Inc. Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor
US20110318415A1 (en) * 2009-03-09 2011-12-29 Chun Li Hollow Gold Nanospheres (HAuNSs) and HAuNSs-Loaded Microspheres Useful in Drug Delivery
CN103209704B (zh) 2010-04-22 2017-10-27 细胞内治疗公司 有机化合物
ES2791715T3 (es) 2010-12-16 2020-11-05 Sunovion Pharmaceuticals Inc Películas sublinguales
AU2013245702A1 (en) * 2012-04-14 2014-11-13 Intra-Cellular Therapies, Inc. Organic compounds
AR092568A1 (es) 2012-09-14 2015-04-22 Abbvie Deutschland Derivados triciclicos de quinolinas y de quinoxalinas
WO2014145192A1 (en) * 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2015085004A1 (en) 2013-12-03 2015-06-11 Intra-Cellular Therapies, Inc. Novel methods
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
KR20170012210A (ko) * 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
EP4512394A3 (en) 2015-06-03 2025-10-22 Triastek, Inc. Dosage forms and use thereof
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
DK3407889T3 (da) * 2016-03-25 2021-08-09 Intra Cellular Therapies Inc Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
US20200392135A1 (en) * 2016-03-25 2020-12-17 Intra-Cellular Therapies, Inc. Organic compounds
US11014925B2 (en) * 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
WO2018106916A1 (en) 2016-12-07 2018-06-14 Concert Pharmaceuticals, Inc. Deuterated quinoxaline compounds
WO2018175969A1 (en) * 2017-03-24 2018-09-27 Intra-Cellular Therapies, Inc. Novel compositions and methods
WO2019102240A1 (en) 2017-11-27 2019-05-31 Egis Gyógyszergyár Zrt. Method for the manufacture of lumateperone and its salts
US11839614B2 (en) * 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
US11980617B2 (en) * 2018-03-16 2024-05-14 Intra-Cellular Therapies, Inc. Methods of treating acute depression and/or acute anxiety
CN112088004A (zh) * 2018-03-23 2020-12-15 细胞内治疗公司 有机化合物
US12144808B2 (en) * 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
US12478623B2 (en) * 2019-09-25 2025-11-25 Intra-Cellular Therapies, Inc. Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor
AU2023272111A1 (en) * 2022-05-18 2024-11-28 Intra-Cellular Therapies, Inc. Novel methods

Also Published As

Publication number Publication date
CA3148326A1 (en) 2015-06-11
KR102373288B1 (ko) 2022-03-10
MX2021007665A (es) 2022-09-09
IL305990A (en) 2023-11-01
US20210322433A1 (en) 2021-10-21
JP2021075566A (ja) 2021-05-20
WO2015085004A1 (en) 2015-06-11
US20250360140A1 (en) 2025-11-27
IL246002B2 (en) 2024-11-01
KR102692169B1 (ko) 2024-08-05
AU2019200301B2 (en) 2020-01-30
AU2019200301A1 (en) 2019-02-07
JP2025032193A (ja) 2025-03-11
EP3076967B1 (en) 2021-07-28
EP3666271A1 (en) 2020-06-17
US20180200256A1 (en) 2018-07-19
ES2893621T3 (es) 2022-02-09
AU2021290277A1 (en) 2022-01-27
KR20210049200A (ko) 2021-05-04
US10960010B2 (en) 2021-03-30
CN114366741A (zh) 2022-04-19
AU2020202386A1 (en) 2020-04-30
US10322134B2 (en) 2019-06-18
KR20220103822A (ko) 2022-07-22
RU2682658C1 (ru) 2019-03-20
IL246002A0 (en) 2016-07-31
CN105939712A (zh) 2016-09-14
US11026951B2 (en) 2021-06-08
AU2020202386B2 (en) 2021-09-30
CA3148303A1 (en) 2015-06-11
AU2021290277B2 (en) 2023-07-20
US20240024334A1 (en) 2024-01-25
IL305990B1 (en) 2025-08-01
MX2016007219A (es) 2016-09-16
IL293523A (en) 2022-08-01
EP3076967A1 (en) 2016-10-12
MX383855B (es) 2025-03-14
US10960009B2 (en) 2021-03-30
JP7262495B2 (ja) 2023-04-21
KR20210101326A (ko) 2021-08-18
KR20210049199A (ko) 2021-05-04
JP2023089113A (ja) 2023-06-27
AU2014360452A1 (en) 2016-07-21
AU2014360452B2 (en) 2018-10-18
MX2022011140A (es) 2022-10-13
DK3076967T3 (da) 2021-10-25
JP6475727B2 (ja) 2019-02-27
JP2019077724A (ja) 2019-05-23
JP6874028B2 (ja) 2021-05-19
CA3205777A1 (en) 2015-06-11
KR20230023817A (ko) 2023-02-17
CA3148303C (en) 2024-02-27
US9956227B2 (en) 2018-05-01
KR102287288B1 (ko) 2021-08-06
EP3076967A4 (en) 2017-05-10
KR20230058736A (ko) 2023-05-03
MX395458B (es) 2025-03-25
IL246002B (en) 2022-07-01
US20160310502A1 (en) 2016-10-27
KR102495941B1 (ko) 2023-02-06
US20190290655A1 (en) 2019-09-26
IL321987A (en) 2025-09-01
IL305990B2 (en) 2025-12-01
KR102421656B1 (ko) 2022-07-15
US20190328745A1 (en) 2019-10-31
AU2014360452C1 (en) 2019-05-16
KR102372145B1 (ko) 2022-03-07
CA2932610C (en) 2023-08-22
IL293523B2 (en) 2024-02-01
BR112016012781A2 (pt) 2017-08-08
AU2020202386C1 (en) 2022-04-07
JP2016539144A (ja) 2016-12-15
IL293523B1 (en) 2023-10-01
US20190298730A1 (en) 2019-10-03
KR20240119197A (ko) 2024-08-06
HUE056496T2 (hu) 2022-02-28
CA2932610A1 (en) 2015-06-11
PT3076967T (pt) 2021-10-07
JP7600299B2 (ja) 2024-12-16
KR20160093055A (ko) 2016-08-05

Similar Documents

Publication Publication Date Title
PL3076967T3 (pl) Metody leczenia objawów rezydualnych schizofrenii
IL283943A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
LT2885010T (lt) Tautopatijos gydymo būdai
EP2968208A4 (en) TREATMENT OF CATAPLEXIA
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
LT2981255T (lt) Empagliflozino terapiniai panaudojimo būdai
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
LT3007726T (lt) Tautopatijos gydymo būdai
DK3021838T3 (da) Behandling af fedme
PT3626270T (pt) Tratamento de doenças cardiovasculares
PT2953948T (pt) Antagonistas de integrina fluorada
HRP20182138T1 (hr) Modificirani serpini za liječenje poremećaja s krvarenjem
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
EP2988708A4 (en) ANKLE SUPPORT
LT3563837T (lt) Terapija bakteriofagu
EP2982331A4 (en) Treatment tool
EP2945942A4 (en) Voriconazole IMMUNOASSAY
IL242220A0 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
HRP20190219T1 (hr) Spojevi za tretman pretilosti i postupci za njihovu uporabu
DK2976101T3 (da) Behandlingsfremgangsmåde
EP2996772A4 (en) Methods for the treatment of neurodegeneration
DK2968606T3 (da) Behandling af autoimmune sygdomme
DK3041506T3 (da) Behandlingsfremgangsmåde
HUE042691T2 (hu) Tiazolo-pirimidinon felhasználása gyulladásos bélbetegségek kezeléséhez
FI10329U1 (fi) Kaasujen käsittelylaitteisto